The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database
Year: 2019
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Only few studies, with small patient cohorts, have evaluated the effect of radiotherapy (RT) for metaplastic breast cancer (MBC). Hence, it is important to investigate the role of RT in MBC survival using a large population-database. METHODS: A retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) from 1973 to 2015 was performed. We compared MBC patients with or without RT for overall survival (OS) and breast cancer-specific survival (BCSS) using univariate and multivariate Cox proportional hazard regressions before and after propensity score matching (PSM). RESULTS: From a total of 2267 patients diagnosed with MBC between 1998 and 2015, 1086 (47.9%) received RT. In the multivariate analysis before PSM, RT provided a better OS (HR 0.73; 95% CI 0.61-0.88; p = 0.001) and BCSS (HR 0.71; 95% CI 0.58-0.88; p = 0.002). Multivariate analyses after PSM (n = 1066) confirmed that patients receiving RT (n = 506) survived longer than those without RT (OS, HR 0.64; 95% CI 0.51-0.80; p < 0.001 and BCSS, HR 0.64; 95% CI 0.50-0.83; p = 0.001). A longer OS was observed when RT was given to older patients (p = 0.001) and in case of large tumor size (p = 0.002). Intriguingly, patients with N0 stage showed better OS after RT (HR 0.69, P = 0.012). CONCLUSIONS: Our findings support the beneficial effect of RT for MBC patients. In particular, older patients or with large tumor size have a greater survival benefit from RT. In conclusion, we have assessed the importance of the use of RT in MBC as survival factor and this could lead to the development of guidelines for this rare sub-type of tumors.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,890
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Ladies Leukemia League, National Natural Science Foundation of China, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences, Moonshot Research and Development Program, Common Fund, Natural Science Foundation of Zhejiang Province
Awards: G1125512807, G2226474896, Novel extra cellular RNA-based combinatorial RNA inhibition therapy, G2663453512, G3401145678, Viral miRs and cellular miRs in sepsis, G5086248425, G5306837625, G6077865511, G685229775, G6853824701, G6975828589, Protein-coding and non-coding RNA biomarkers for early detection of CLL, miR-155 targeted therapeutics for precision medicine in lung cancer, G7905850378, G8274656085, 褪黑素在干细胞软骨再生中的抗炎/抗氧化作用及其对骨关节炎治疗的研究, G9000065446
OpenAlex ID: W2976499962
